Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations
Date:10/30/2009

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 3, 2009 at approximately 2:10 p.m. Eastern time, and at the Lazard Capital Markets 6th Annual Healthcare Conference in New York on November 18, 2009 at approximately 9 a.m. Eastern time. The presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com. The webcasts will be available for 30 days following the events.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,200 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended June 30, 2009, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

    Contact:

    Paula Izidoro
    Investor Relations
    858-410-8904

SOURCE Gen-Probe Incorporated


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
2. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
4. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
7. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast
9. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
10. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CREEK, Calif. , Mar 29, 2017 /PRNewswire/ ... cervical-fusion technology, announced the addition of two industry ... Lynch has joined the company to lead ... assuming International leadership.  Together, Mr. Lynch and Mr. ... experience.  Mr. Lynch joins the ...
(Date:3/29/2017)... March 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical ... non-invasive medical devices for pain management, stroke rehabilitation, cardiac ... host the Company,s 2016 full-year investor webcast on Monday, April ... The Company expects to file its 2016 full ... ...
(Date:3/29/2017)... , March 29, 2017 Optometrists ... patients as the highest standard in quality and ... Vision introduces its objective Wavefront-driven refraction technologies and ... approach. This enables an unprecedented level of refraction ... exceptional vision relegated to Topgun Navy fighter pilots, ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... March 30, 2017 , ... Although many people are wary of baring ... wary of baring their skin for other reasons, including unsightly skin conditions like dermatitis, ... get the skin prepared for the summer weather and allow individuals to hit the ...
(Date:3/30/2017)... ... ... manicurist from Greet, S.C., wants to offer people a new way to care for their ... feet, so I know the importance of proper foot care," he said. "In order to ... , The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... ... , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S ... serve as the official title sponsor of the Baltimore Women’s Classic, the largest all ... women will walk or run the course around the Baltimore Inner Harbor. Mercy has ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
Breaking Medicine News(10 mins):